Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shukun Raises $29.5 Million for AI-based Hospital Diagnosis in China

publication date: Feb 20, 2019

Shukun Technology, a Beijing medical artificial intelligence company, raised $29.5 million in a series B financing round led by China Creation Ventures, a VC firm focusing on the China TMT. Shukun combines expert and machine intelligence to improve the diagnostic experience in hospitals. Its lead product, CoronaryDoc, is being tested in clinical trials as a first-in-class AI product to diagnose heart disease. The company said it aims to address the shortage of specialized MDs in China. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital